Sandoz To Acquire Antifungal Agent Mycamine From Astellas Pharma
BASEL (dpa-AFX) - Sandoz said it has entered into an agreement to acquire worldwide product rights for systemic antifungal agent…
9,330€
-1,55%
Echtzeit-Aktienkurs Astellas Pharma Inc.
Bid:
Ask:
Nachrichten zur Astellas Pharma Inc. Aktie
Astellas Transfers MYCAMINE® Product Worldwide
TOKYO, Jan. 23, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to…
Astellas Pharma: FDA Lifts Clinical Hold On Trial Of AT845 In Late-Onset Pompe Disease
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said Friday that the U.S. Food and Drug Administration has lifted the…
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
TOKYO, Jan. 20, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…
Leap rebounds as Astellas posts Phase 3 data for rival cancer candidate
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions
TOKYO, Jan. 19, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…
Antibiotics market to grow by 5.11% Y-O-Y from 2022 to 2023: Rising prevalence of infectious diseases will drive growth - Technavio
NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Antibiotics market insights - Vendors: 15+, Including Abbott Laboratories, AbbVie Inc., Armata Pharmaceuticals…
Selecta Biosciences stock rises 10% on license deal with Astellas for Xork
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Selecta Biosciences Shares Rise 11% After Licensing Deal With Astellas Pharma
Selecta Biosciences Shares Rise 11% After Licensing Deal With Astellas Pharma...…
Astellas, Twist Bioscience team up for discovering antibodies for multiple targets
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies product, for the…
Basilea erhält dank guter Cresemba-Umsätze Meilensteinzahlung von Astellas
Pharma - Basilea erhält eine Meilensteinzahlung vom Partner Astellas....…
Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basilea
Ad hoc announcement pursuant to Art. 53 LR...…
Fortgesetzt gute Cresemba® (Isavuconazol)-Verkaufszahlen von Astellas in den USA lösen CHF 20 Mio. Umsatzmeilensteinzahlung an Basilea aus
Ad hoc-Mitteilung gemäss Art. 53 KR...…